The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; Celgene; Clovis Oncology; CureVac; Eisai; Genomic Health; GlaxoSmithKline; Immunomedics; Janssen-Cilag; Lilly; MSD; Novartis; Pfizer; PharmaMar; Roche; Seagen; Tesaro
Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.
 
Carsten Denkert
Stock and Other Ownership Interests - Sividon Diagnostics
Honoraria - Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Merck; Molecular Health; MSD Oncology
Research Funding - Myriad Genetics (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent application WO2020109570A1 - cancer immunotherapy; Patent applications WO2015114146A1 and WO2010076322A1- therapy response; VMScope digital pathology software
Travel, Accommodations, Expenses - Roche
 
Frederik Marmé
No Relationships to Disclose
 
Miguel Martin
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; PharmaMar; Roche/Genentech; Taiho Pharmaceutical
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Other Relationship - Novartis; Roche
 
Michael Untch
Honoraria - Agendia (Inst); Art tempi (Inst); AstraZeneca (Inst); Bristol Myer Squibb (Inst); Celgene (Inst); Daiji Sankyo (Inst); MSD Oncology (Inst); Mundipharma (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Abbvie (Inst); Agendia (Inst); Amgen (Inst); Celgene (Inst); Lilly (Inst); MSD Oncology (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Seagen (Inst)
 
Herve R. Bonnefoi
Honoraria - Roche
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Agnieszka Katarzyna Witkiewicz
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Angela DeMichele
No Relationships to Disclose
 
Laura van 't Veer
Employment - Agendia
Leadership - Agendia
Stock and Other Ownership Interests - Agendia
 
Nicole Mc Carthy
No Relationships to Disclose
 
Karen A. Gelmon
Honoraria - AstraZeneca; Merck Sharp & Dohme; Novartis Canada Pharmaceuticals Inc; Seagen
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Genomic Health; Janssen Oncology; Lilly; Merck; Mylan; NanoString Technologies; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst)
Expert Testimony - Genentech
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Repare Therapeutics; Roche; Taiho Pharmaceutical; Zeno pharmaceuticals
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Pfizer (Inst); Roche (Inst)
 
Federico Rojo
No Relationships to Disclose
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst)
 
Julia Teply-Szymanski
No Relationships to Disclose
 
Yuan Liu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Masakazu Toi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Devicor Medical Products; Eisai; Exact Sciences; Konica Minolta; Kyowa Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Shimadzu; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Athenex; Bertis; BMS; Daiichi Sankyo; Kansai Medical; Kyowa Kirin; Lilly; Lux Biosciences; Lux Biosciences; Terumo
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer
Research Funding - AFI technology; Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Japan Breast Cancer Research Group; Kyoto Breast cancer Research Network; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Shimadzu; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Travel, Accommodations, Expenses - Eisai; Takeda
Other Relationship - Japan Breast Cancer Research Group; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research
 
Michael Gnant
Employment - Sandoz (I)
Honoraria - Amgen; AstraZeneca; Lilly; Novartis
Consulting or Advisory Role - Daiichi-Sankyo; LifeBrain; Lilly; Tolmar; Veracyte
 
Karsten Ernst Weber
No Relationships to Disclose
 
Sibylle Loibl
Honoraria - Chugai Pharma
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Samsung (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Immunomedics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending EP14153692.0 (Inst)